Selloff or Market Correction? Either Way, Here's What to Do NextSee Overvalued Stocks

Moderna to hire around 2,000 employees amid mRNA development push

Published 03/10/2023, 11:19 AM
Updated 03/10/2023, 02:41 PM
© Reuters. FILE PHOTO: A sign marks the headquarters of the coronavirus disease (COVID-19) vaccine maker Moderna in Cambridge, Massachusetts, U.S., April 28, 2022.   REUTERS/Brian Snyder/File Photo
MRNA
-

(Reuters) -Moderna Inc said on Friday it was planning to hire about 2,000 employees globally by 2023-end and set up new offices on the U.S. West Coast, as it aims to scale up development of new products amid declining COVID vaccine sales.

The COVID vaccine maker said it will open new offices in California and Seattle, adding that its Genomics unit will expand to south San Francisco.

The latest move comes at a time when Moderna (NASDAQ:MRNA) has been working on developing vaccines for skin cancer, flu and respiratory syncytial virus (RSV) using its mRNA technology, which if approved would significantly boost the biotech company that currently relies heavily on its COVID-19 shot.

© Reuters. FILE PHOTO: A sign marks the headquarters of the coronavirus disease (COVID-19) vaccine maker Moderna in Cambridge, Massachusetts, U.S., April 28, 2022.   REUTERS/Brian Snyder/File Photo

Last month, Moderna forecast rising costs for 2023 and a decline in COVID vaccine sales, raising concerns that the company could post a loss this year.

The firm had about 3,900 full-time employees as of Dec. 31, according to a regulatory filing.Shares of the Cambridge, Massachusetts-based company were up more than 2% at $140.22 in afternoon trade.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.